Italia markets closed

ADC Therapeutics SA (ADCT)

NYSE - NYSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
3,4300-0,0100 (-0,29%)
Alla chiusura: 04:00PM EDT
3,3100 -0,12 (-3,50%)
Dopo ore: 07:50PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,4400
Aperto3,4100
Denaro2,0100 x 1200
Domanda3,3300 x 800
Min-Max giorno3,3020 - 3,5700
Intervallo di 52 settimane0,3600 - 6,0400
Volume771.722
Media Volume571.641
Capitalizzazione330,055M
Beta (mensile su 5 anni)1,70
Rapporto PE (ttm)N/D
EPS (ttm)-2,7700
Prossima data utili06 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A10,00
  • GlobeNewswire

    Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO

    LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today announces the appointment of Francesca Zammarchi, Ph.D., as Chief Scientific Officer (CSO). Dr. Zammarchi joins Myricx as it accelerates the development of its pipeline of ADCs based on its first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform. She

  • GlobeNewswire

    ADC Therapeutics to Participate in September Investor Conferences

    LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September. Details of the events are as follows: Morgan Stanley Global Healthcare Conference - fireside chat on Monday, September 11th from 2:15 p.m. – 2:45 p.m. ETCantor Global Healthcare Conference - fireside chat on Wednesday, September 27th from 4:45 p.m. – 5:15 p.m. ET Live webcasts of the fires

  • GlobeNewswire

    ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

    LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA® in patients with r/r non-Hodgkin lymphoma to be highlighted in poster; actively enrolling patients in bispecific combination arms LAUSANNE, Switzerland, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that two ZYNLONTA® (loncastuximab tesirine-lpyl) abstracts have bee